Suppr超能文献

糖皮质激素对患者生活质量的影响:一项定性研究,评估类固醇PRO在炎症性胃肠病、呼吸系统疾病和皮肤病患者中的表面效度和可行性。

Impact of glucocorticoids on patients' quality of life: a qualitative study assessing face validity and feasibility of the Steroid PRO in patients with inflammatory gastroenterology, respiratory and dermatology conditions.

作者信息

Sweeney Anne-Marie T, Bridgewater Susan, Orme Jen, Sattui Sebastian E, Sharp Michelle, Richards Pamela, Silverthorne Christine A, Arthurs Elizabeth, Creed Tom, Osborne Genevieve, Dunhill Giles, Dawson Jill, Dures Emma, Barratt Shaney L, Ramonell Richard P, Patton Timothy, Goodman Susan M, Hill Catherine L, Mackie Sarah L, Ndosi Mwidimi, Robson Joanna C

机构信息

University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Center for Health and Clinical Research, University of the West of England, Bristol, UK.

出版信息

BMJ Open. 2025 Feb 5;15(2):e089225. doi: 10.1136/bmjopen-2024-089225.

Abstract

OBJECTIVES

The Steroid PRO is a treatment-specific patient-reported outcome questionnaire which measures the impact of glucocorticoids on health-related quality of life. It has 15 items grouped into 4 domains (Social impact, Impact on Appearance, Psychological Impact and Treatment Concerns). Initially developed and validated in rheumatic diseases, the Steroid PRO demonstrates potential for broader application in patients with other inflammatory conditions. The objective of this study was to assess face validity, content validity and feasibility of the Steroid PRO in (1) patients treated with glucocorticoids for inflammatory respiratory, dermatological and gastroenterological conditions and (2) clinicians working within these specialties in the UK and USA.

DESIGN

Qualitative study with semistructured cognitive interview methods.

SETTING

Online or face-to-face interviews with participants from seven departments across three secondary care hospitals in the UK and USA.

PARTICIPANTS

Inclusion criteria: (1) Adult patients with inflammatory respiratory, gastroenterological and dermatological conditions treated with glucocorticoids and (2) healthcare professionals (HCPs) working in respiratory, dermatology and gastroenterology departments in the UK and USA.

RESULTS

Purposive sampling to ensure a range of patient and HCP participants. A total of 42 patient participants were recruited, from respiratory/pulmonology (n=14, 33.3%), dermatology (n=13, 31.0%) and gastroenterology (n=15, 35.8%) medical departments; 32 in the UK and 10 from the USA. Mean age 48.2 years (range 22-71) and 19 (45.2%) were female. Patient participants had a range of inflammatory lung, skin and bowel conditions, with a spectrum of demographics and patterns of glucocorticoid use. 14 HCPs participated from the UK (9) and USA (5). Face validity: 97% (30/31) patients and 100% (14/14) HCPs reported the Steroid PRO was 'relevant or very relevant' to them and their disease.

FEASIBILITY

97% (30/31) patients and 100% (14/14) HCPs reported the Steroid PRO was 'easy or very easy to complete'. Patients reported that the four domains of the Steroid PRO had relevance to them and that it was validating to see their concerns represented: 'It's obvious you guys know what you're talking about-these are my issues. It's very validating when you realise it's not just you. These problems are real and they matter.… These are not questions my doctor asks me about. Doctors never ask about psychosocial aspects. It would be really great if they used this' (female patient with asthma). Patients and clinicians felt the Steroid PRO would be suitable for use in clinical practice within their specialties and would aid in understanding of the impact of glucocorticoids.

CONCLUSIONS

The Steroid PRO demonstrated face validity and content validity for assessing the impact of glucocorticoids in patients with inflammatory respiratory, gastroenterological and dermatological conditions. Additionally, the feasibility of using the Steroid PRO with both patients and HCPs has been established. Future work should include quantitative testing of the Steroid PRO as an outcome measure within clinical trials in these conditions.

TRIAL REGISTRATION NUMBER

NCT06314451.

摘要

目的

类固醇PRO是一种针对特定治疗的患者报告结局问卷,用于衡量糖皮质激素对健康相关生活质量的影响。它有15个项目,分为4个领域(社会影响、对外观的影响、心理影响和治疗相关问题)。类固醇PRO最初是在风湿性疾病中开发并验证的,显示出在其他炎症性疾病患者中更广泛应用的潜力。本研究的目的是评估类固醇PRO在以下方面的表面效度、内容效度和可行性:(1)接受糖皮质激素治疗的炎症性呼吸道、皮肤病和胃肠病患者;(2)在英国和美国这些专科工作的临床医生。

设计

采用半结构化认知访谈方法的定性研究。

地点

对来自英国和美国三家二级护理医院七个科室的参与者进行在线或面对面访谈。

参与者

纳入标准:(1)接受糖皮质激素治疗的炎症性呼吸道、胃肠病和皮肤病成年患者;(2)在英国和美国呼吸科、皮肤科和胃肠病科工作的医疗专业人员(HCPs)。

结果

采用目的抽样以确保纳入一系列患者和HCP参与者。共招募了42名患者参与者,分别来自呼吸/肺病科(n = 14,33.3%)、皮肤科(n = 13,31.0%)和胃肠病科(n = 15,35.8%);32名来自英国,10名来自美国。平均年龄48.2岁(范围22 - 71岁),19名(45.2%)为女性。患者参与者患有一系列炎症性肺部、皮肤和肠道疾病,具有不同的人口统计学特征和糖皮质激素使用模式。14名HCP参与者来自英国(9名)和美国(5名)。表面效度:97%(30/31)的患者和100%(14/14)的HCP报告类固醇PRO对他们及其疾病“相关或非常相关”。

可行性

97%(30/)的患者和)的HCP报告类固醇PRO“易于或非常易于完成”。患者报告类固醇PRO的四个领域与他们相关,看到自己的担忧被体现出来很有意义:“很明显你们知道自己在说什么——这些就是我的问题。当你意识到不只是你有这些问题时,这很有意义。这些问题是真实存在且很重要的……这些不是我的医生问我的问题。医生从不问心理社会方面的问题。如果他们使用这个问卷那就太好了”(患有哮喘的女性患者)。患者和临床医生认为类固醇PRO适用于他们专科的临床实践,并有助于了解糖皮质激素的影响。

结论

类固醇PRO在评估糖皮质激素对炎症性呼吸道胃肠病和皮肤病患者的影响方面显示出表面效度和内容效度。此外,已证实类固醇PRO在患者和HCP中使用的可行性。未来的工作应包括在这些疾病的临床试验中对类固醇PRO作为结局指标进行定量测试。

试验注册号

NCT06314451

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/434b/11800201/fc72840afd1f/bmjopen-15-2-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验